Iovance Biotherapeutics has recently faced a dramatic downturn in stock value, plummeting 44% in a short span as investors reacted to the updated financial projections for
2025.
This article delves into the implications of these revised projections, the impact on investor sentiment, and what the future might hold for the biotechnology firm.
